Replies to post #237823 on Biotech Values

[DewDiligence]

ABT says current procedure volume for its medical devices is +3% from pre-COVID period (early 2020).

[DewDiligence]

ABT 2Q21 results—2021_non-GAAP-EPS_guidance_remains $4.30-4.50:

https://abbott.mediaroom.com/2021-07-22-Abbott-Reports-Second-Quarter-2021-Results